BeiGene Reports First Quarter 2024 Financial Results and Business Updates

Go back to BeiGene Reports First Quarter 2024 Financial Results and Business Updates

BeiGene, Ltd. (BGNE) PT Lowered to $283 at Jefferies

May 9, 2024 7:26 AM EDT

Jefferies analyst Kelly Shi lowered the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $283.00 (from $287.00) while maintaining a Buy rating.

The analyst comments "The $747M product rev beat (+8%) $694M cons, driven by sales growth all around globally. Brukinsa's $489M sales ($351M US) grew +18% despite Q1... More